Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 20:14:1211426.
doi: 10.3389/fendo.2023.1211426. eCollection 2023.

Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives

Lothar Seefried  1 , Martin Biosse Duplan  2   3   4 , Karine Briot  5 , Michael T Collins  6 , Rachel Evans  7 , Pablo Florenzano  8   9 , Neil Hawkins  7 , Muhammad Kassim Javaid  10 , Robin Lachmann  11 , Leanne M Ward  12
Affiliations

Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives

Lothar Seefried et al. Front Endocrinol (Lausanne). .

Abstract

X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disease with multisystem impact that typically begins to manifest in early childhood. Two treatment options exist: oral phosphate in combination with active vitamin D ("conventional therapy") and a fully human monoclonal anti-FGF23 antibody, burosumab. The clinical benefit of conventional therapy in adults is limited, and poor tolerance and complications are common. Burosumab was first approved as a treatment for XLH in 2018 and its disease-modifying benefits in clinical trials in children suggest burosumab treatment could also alter the disease course in adults. Without long-term clinical data on multiple XLH-related sequelae available, the results of an elicitation exercise are reported, in which eight global experts in XLH posited how long-term treatment with burosumab is anticipated to impact the life course of clinical sequelae in adults with XLH. Based on their clinical experiences, the available evidence and their disease understanding, the experts agreed that some long-term benefits of using burosumab are likely in adults with XLH even if they have a misaligned skeleton from childhood. Burosumab treatment is anticipated to reduce the incidence of fractures and halt the progression of clinical sequelae associated with conventional therapy. While the trajectories for established dental abscesses are not expected to improve with burosumab treatment, dental abscess development may be prevented. Starting treatment with burosumab in childhood to increase the likelihood of an aligned skeleton and continuation into and throughout adulthood to maintain euphosphatemia may optimize patient outcomes, although future real-world investigation is required to support this hypothesis.

Keywords: X-linked hypophosphatemia; burosumab; fibroblast growth factor 23; hypophosphatemia; phosphate metabolism.

PubMed Disclaimer

Conflict of interest statement

LS has received honoraria and institutional grant support from Kyowa Kirin. MD has received honoraria and institutional grant support from Kyowa Kirin. KB has received honoraria, institutional grant support from Kyowa Kirin and participated in clinical trials with Ultragenyx and Kyowa Kirin. PF has received institutional grant support from Ultragenyx and honoraria as a consultant from Kyowa Kirin. MJ has received honoraria and institutional grant support from Kyowa Kirin and participated in clinical trials with Ultragenyx. LW has been a consultant to, and participated in clinical trials, with Ultragenyx funds to Dr Ward’s institution. NH is an employee of Visible Analytics, the company that was compensated for the elicitation exercise by Kyowa Kirin. RE is a former employee of Visible Analytics, the company that was compensated for the elicitation exercise by Kyowa Kirin. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. This study was sponsored by Kyowa Kirin International. The authors received no specific funding for this work.

Figures

Figure 1
Figure 1
Format of questionnaire.
Figure 2
Figure 2
Flowchart of expert elicitation process.
See this image and copyright information in PMC

References

    1. The HYP Consortium . A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet (1995) 11:130–6. doi: 10.1038/ng1095-130 - DOI - PubMed
    1. ADHR Consortium . Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet (2000) 26:345–8. doi: 10.1038/81664 - DOI - PubMed
    1. Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. . FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis (2019) 14:58. doi: 10.1186/s13023-019-1014-8 - DOI - PMC - PubMed
    1. Leung J, Crook M. Disorders of phosphate metabolism. J Clin Pathol (2019) 72:741–7. doi: 10.1136/jclinpath-2018-205130 - DOI - PubMed
    1. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, et al. . Human fibroblast growth factor-23 mutants suppress na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem (2003) 278:2206–11. doi: 10.1074/jbc.M207872200 - DOI - PubMed

Publication types

LinkOut - more resources